ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
155.75 EUR
+1 (+0.65%)
Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 55 industry peers in the Pharmaceuticals industry. ZEG scores excellent on profitability, but there are concerns on its financial health. While showing a medium growth rate, ZEG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
In the past year ZEG had a positive cash flow from operations.
In the past 5 years ZEG has always been profitable.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.21%, ZEG is in the better half of the industry, outperforming 67.27% of the companies in the same industry.
ZEG has a Return On Equity of 20.48%. This is in the better half of the industry: ZEG outperforms 67.27% of its industry peers.
The Return On Invested Capital of ZEG (14.42%) is better than 70.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 13.92%.
The last Return On Invested Capital (14.42%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (16.17%) is better than 65.45% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
With a Operating Margin value of 24.34%, ZEG perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
ZEG's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 81.90%, ZEG belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
Compared to 1 year ago, ZEG has about the same amount of shares outstanding.
ZEG has more shares outstanding than it did 5 years ago.
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.95 indicates that ZEG is not in any danger for bankruptcy at the moment.
ZEG has a better Altman-Z score (5.95) than 81.82% of its industry peers.
ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.41, ZEG is in line with its industry, outperforming 56.36% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.61) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 5.95 |
ROIC/WACC1.6
WACC9.01%
2.3 Liquidity
ZEG has a Current Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ZEG (0.88) is worse than 81.82% of its industry peers.
A Quick Ratio of 0.69 indicates that ZEG may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, ZEG is doing worse than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.61% over the past year.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.17% yearly.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.45%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.89, the valuation of ZEG can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.46, ZEG is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 17.14, the valuation of ZEG can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as ZEG.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (36.10), we can say ZEG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 17.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than the industry average as 69.09% of the companies are valued more cheaply.
67.27% of the companies in the same industry are cheaper than ZEG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.89 | ||
| EV/EBITDA | 28.44 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.44
PEG (5Y)1.07
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.81%. Purely for dividend investing, there may be better candidates out there.
ZEG's Dividend Yield is comparable with the industry average which is at 2.86.
Compared to the average S&P500 Dividend Yield of 2.32, ZEG is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
FRA:ZEG (12/5/2025, 7:00:00 PM)
155.75
+1 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap482.91B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target165.09 (6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.56
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)3.4%
PT rev (3m)2.51%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-1.88%
EPS NY rev (1m)0.05%
EPS NY rev (3m)0.09%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 17.14 | ||
| P/S | 9.69 | ||
| P/FCF | 58.89 | ||
| P/OCF | 37.21 | ||
| P/B | 12.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.44 |
EPS(TTM)7.83
EY5.03%
EPS(NY)9.09
Fwd EY5.84%
FCF(TTM)2.64
FCFY1.7%
OCF(TTM)4.19
OCFY2.69%
SpS16.07
BVpS12.69
TBVpS-3.74
PEG (NY)1.44
PEG (5Y)1.07
Graham Number47.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 5.95 |
F-Score7
WACC9.01%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 19.89 and the Price/Book (PB) ratio is 12.28.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.